Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study-Reference-Cited by-同舟云学术

Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study

Published:2021-01 Issue: Volume:69 Page:30-37
ISSN:1045-1056
Container-title:Biologicals
language:en
Short-container-title:Biologicals

Author:

Alsamil Ali M.,Giezen Thijs J.^ORCID,Egberts Toine C.,Leufkens Hubert G.,Gardarsdottir Helga

Publisher

Elsevier BV

Subject

Pharmacology,General Immunology and Microbiology,Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Reference48 articles.

1. The process defines the product: what really matters in biosimilar design and production?;Vulto;Rheumatology,2017

2. Inc, A., HUMIRA (adalimumab) injection, full prescribing information. AbbVie Inc.

3. Adalimumab biosimilars in Europe: an overview of the clinical evidence;Bellinvia;BioDrugs,2019

4. Principles of analytical similarity assessment;Vandekerckhove,2018

5. Transparency in drug regulation: public assessment reports in Europe and Australia;Papathanasiou;Drug Discov Today,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report;Clinical Pharmacology & Therapeutics;2024-04-28

2. Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars;European Journal of Pharmaceutical Sciences;2022-08

3. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars;Pharmaceuticals;2021-02-25